AstraZeneca Announces Maryland Manufacturing Investment
Ticker: AZN · Form: 6-K · Filed: Nov 24, 2025 · CIK: 901832
| Field | Detail |
|---|---|
| Company | Astrazeneca PLC (AZN) |
| Form Type | 6-K |
| Filed Date | Nov 24, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $2 billion, $50 billion, $20 billion |
| Sentiment | neutral |
Sentiment: neutral
Topics: manufacturing, investment, sec-filing
TL;DR
AstraZeneca investing in Maryland manufacturing, filing 6-K.
AI Summary
AstraZeneca PLC announced a manufacturing investment in Maryland, USA, on November 24, 2025. The company, headquartered in Cambridge, UK, is filing a Form 6-K report with the SEC. This filing is related to their operations and does not specify a dollar amount for the investment.
Why It Matters
This investment signals AstraZeneca's commitment to expanding its manufacturing capabilities in the US, potentially impacting supply chains and local economies.
Risk Assessment
Risk Level: low — The filing is a routine report of foreign issuer and does not contain significant financial or operational news that would immediately impact risk.
Key Players & Entities
- AstraZeneca PLC (company) — Filer of the report
- 001-11960 (company) — SEC File Number
- 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom (company) — Registrant's business address
- 20251124 (date) — Filing date
FAQ
What type of report is AstraZeneca PLC filing?
AstraZeneca PLC is filing a Form 6-K, which is a Report of Foreign Issuer.
What is the Commission File Number for AstraZeneca PLC?
The Commission File Number for AstraZeneca PLC is 001-11960.
Where is AstraZeneca PLC's business address?
AstraZeneca PLC's business address is 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge CB2 0AA, United Kingdom.
What is the filing date of this report?
The filing date of this report is November 24, 2025.
Does AstraZeneca PLC file annual reports under Form 20-F or 40-F?
AstraZeneca PLC indicates it files annual reports under cover of Form 20-F.
Filing Stats: 918 words · 4 min read · ~3 pages · Grade level 17.3 · Accepted 2025-11-24 06:54:12
Key Financial Figures
- $2 billion — ;     AstraZeneca plans $2 billion manufacturing investment in Maryland, s
- $50 billion — year, advancing AstraZeneca's historic $50 billion commitment to medicines manufacturing a
- $20 billion — 2025, AstraZeneca created approximately $20 billion of overall value to the American econom
Filing Documents
- a6308i.htm (6-K) — 24KB
- 0001654954-25-013401.txt ( ) — 25KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.     AstraZeneca PLC     Date: 24 November 2025     By: /s/ Matthew Bowden   Name: Matthew Bowden   Title: Company Secretary